Press releases
Find out more about Ferring latest announcements.
Press releases
-
Ferring Advances Three Studies in ADSTILADRIN® (nadofaragene firadenovec-vncg) Clinical Trial Program
-Ferring activates first sites in a three-arm study of ADSTILADRIN as a monotherapy or in combination with chemotherapy or an immune checkpoint inhibitor in high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) Ferring activates first sites in a two-arm study to evaluate safety and efficacy of ADSTILADRIN as a monotherapy in intermediate-risk NMIBC (IR NMIBC) Ferring initiates clinical trial […]
-
Ferring Announces U.S. FDA Advisory Committee Meeting for SI-6603 (condoliase), An Investigational Treatment in Lumbar Disc Herniation
-Anesthetic and Analgesic Drug Products Advisory Committee will hold the meeting on January 10, 2025 SI-6603 is an investigational product being studied for the treatment of radicular leg pain associated with lumbar disc herniation in adults About 9 million adults in the U.S. suffer from lumbar disc herniation each year Parsippany, NJ – December 2, 2024 – Ferring Pharmaceuticals and […]
-
Ferring Appreciates the Support of New Jersey and Minnesota as They Issue Proclamations Recognizing November as C. Difficile Infection Awareness Month for Fifth Consecutive Year
-Parsippany, NJ – November 13, 2024 – Ferring Pharmaceuticals is grateful to New Jersey and Minnesota for recognizing November as Clostridioides difficile (C. diff) Infection Awareness Month. This is the fifth year in a row that the offices of Governor Phil Murphy (New Jersey) and Governor Tim Walz (Minnesota) issued proclamations to help educate the public about the severity of […]